Summary:
Hematopoietic stem cell transplantation (HSCT) is the only curative option for patients with hemoglobinopathies. However, fewer than 30% of individuals will have an HLA-identical sibling. Improvement in outcomes after HSCT using unrelated donors (URD), and the development of novel nontoxic preparative regimens may make URD HSCT an option for hemoglobinopathy patients who do not have an HLA-identical sibling donor. The National Marrow Donor Program s (NMDP) maintains a Registry of 4 million volunteer donors, and facilitates URD HSCT for patients with life-threatening blood diseases. In light of the increased representation of minorities in the NMDP registry, donor searches were run in April 2001 for a cohort of 272 thalassemia patients and 77 sickle cell disease (SCD) patients for whom searches had been submitted between 1989 and 2001 in order to determine the current likelihood of finding a potential donor of hematopoietic stem cells for hemoglobinopathy patients. About 59.7% SCD patients 80.2% thalassemia patients will find at least one potential 6/6 HLA matched donor or umbilical cord blood (UCB) unit. All patients will find at least one donor or UCB that is a potential 5/6 HLA match. In conclusion the majority of hemoglobinopathy patients will find at least one potential HLA matched unrelated bone marrow donor or UCB. Bone Marrow Transplantation (2003) 31, 547-550. doi:10.1038/sj.bmt.1703887 Keywords:
transplantation; hematopoietic stem cell transplantation; human leukocyte antigens; umbilical cord blood; HLA typing Hematopoietic stem cell transplantation (HSCT) is the only curative option for patients with hemoglobinopathies such as sickle cell disease (SCD) and thalassemia. In young patients without advanced disease who received a bone marrow transplantation from a matched sibling, the overall survival and disease-free survival were 94 and 84% for SCD and 95 and 90% for thalassemia, respectively.
1,2 However, fewer than one-third of these patients will be found a suitable human leukocyte antigen (HLA) matched related or family donor. 3 In the past, HSCT from unrelated donors (URD) has not been offered to patients with hemoglobinopathies. Since these diseases may be associated with prolonged survival, the increased regimen-related toxicity (RRT) of URD HSCT was considered unacceptable. The worldwide number of alternative donor transplants for hemoglobinopathies remains limited to date. [4] [5] [6] [7] [8] [9] Only four unrelated and 60 HLA-nonidentical-related HSCT for thalassemia were reported to the IBMTR from 1969 to 1998. 10 Recently, URD HSCT has been reported in 32 thalassemia patients. 5 The overall survival was 81.5% and event-free survival was 69%. The National Marrow Donor Program s (NMDP) has facilitated HSCT in three SCD and 15 thalassemia patients. 11 The advent of novel strategies for reduction of RRT, including the use of nonmyeloablative preparative regimens 12, 13 and the improvement in outcomes of URD HSCT, 14 has sparked fresh interest in the consideration of URD HSCT for patients with hemoglobinopathies. NMDP maintains a registry of 4 386 235 volunteer donors, more than half of whom have typing for HLA-A, -B and -DRB1. 15 NMDP has facilitated URD HSCT for 11 009 patients with life-threatening blood diseases. Historically, ethnic minorities have been under-represented in donor registries. [16] [17] [18] Recently, efforts by the NMDP to increase the representation of minorities in the registry has led to a three-to ten-fold increase in the representation of these groups since 1993. 18 ( Table 1 ). The probability of finding a suitable donor has also increased, because of the expansion of the network of registries, which now contain more than 6 million HLA-typed donors worldwide. We attempted to determine the current likelihood of finding at least one potential bone marrow or UCB blood donor for patients with SCD or thalassemia.
Methods
NMDP database was searched to identify individuals with a diagnosis of SCD or thalassemia among persons for whom a donor search had been initiated by the NMDP between 1989 and 2001. To evaluate the probability of a patient with hemoglobinopathy having a potential donor identified, searches were run in April 2001 for this cohort of patients. The number of potential donors identified on each search was determined according to degree of HLA match (HLA-A, -B at serologic level, DRB1 potential allele level match) between patient and donor. More than half the potential donors in the registry are completely typed for HLA-A, -B and -DRB1. For the minority donors, this percentage is higher, with 87.2% African-American donors and 89.3% Asian-Pacific Islander donors being completely typed. While HLA-DRB1 typing is DNA based, it is performed at an intermediate resolution level rather than at a high resolution allele level or the low resolution serologic level. Thus, a match at HLA-DRB1 on a preliminary search can be considered only 'a potential DRB1 allele level match'. High resolution matching is performed when a confirmatory testing is requested.
Results
Between 1989 and 2001, the NMDP conducted donor searches at the request of 272 thalassemia patients and 77 SCD patients. The ethnic composition of the patients for whom searches were run is indicated in Figure 1 . The number of potential HLA-identical, one antigen-mismatched bone marrow and up to two antigen-mismatched umbilical cord blood (UCB) units for these patients was determined. The number of patients for whom 1-2 or X3 potential donors were identified in each matched category were determined. The total number of 6/6 HLAmatched potential stem cell donors for SCD and thalassemia patients was also determined. The proportion of patients with SCD or thalassemia for whom matched or mismatched potential donors were identified is described in Table 2 . Among the SCD patients, 59.7% were found at least one donor or UCB unit that was a 6/6 HLA potential match. All SCD patients were found at least one donor or UCB unit that was 5/6 HLA potential match. Among the thalassemia patients for whom a donor search was conducted, 80.2% was found at least one donor or UCB unit that was a 6/6 HLA potential match while 100% was found at least one donor or UCB unit that is a 5/6 HLA potential match.
Discussion
While less than one-third of patients are likely to have matched sibling donors, only 14% of patients with SCD have been found to have matched sibling donor. 3 Thus, the curative option of HSCT is unavailable to the vast majority of these patients. Continued improvement in the outcome of HSCT from matched URD 19, 20 and the development of nonmyeloablative preparative regimens has renewed interest in the use of URD for patients with hemoglobinopathies. 21 As a result of historic under-representation of minorities in the bone marrow transplantation registries in the US as well as the lack of registries in Africa and Asia, it has been suggested that few patients with SCD or thalassemia are likely to be found a matched donor from the NMDP. The results of this study indicate a continued improvement in the availability of potential donors for patients of color. The likelihood of a patient with SCD or thalassemia finding at least one potentially 6/6 matched donor or UCB unit through the NMDP is 59.7 and 80.2%, respectively. This compares favorably with the finding in 1996-97 that 46% African Americans, 64% Latinos/ Hispanics, 56% Asian Pacific Islanders and 81% Caucasians are likely to be found at least one potential donor. 18 The relatively ready availability of potential donors for thalassemia patients may be indicative of the fact that among patients for whom the search was conducted, the majority were of Caucasian or unknown ethnic origin. Thus, if more searches were submitted for thalassemia patients of Asian origin, the probability of finding a donor for this group as a whole may change. However, these figures demonstrate that the majority of patients with hemoglobinopathies are likely to find at least one potential matched unrelated donor. Moreover, when the search is extended to include 5/6 HLA-matched bone marrow, or 4/6 HLA-matched UCB blood donors, at least one potential donor will be identified for all patients. Once a potential donor has been identified, further evaluation for a possible HSCT may be initiated. At that stage, NMDP staff contact the donors to confirm their willingness and ability to donate bone marrow. Confirmatory testing of donor HLA typing is then conducted. The continued availability of registered donors is termed donor retention. Unavailability of registered donors when confirmatory testing is requested is higher among the minority donors because the donor is not contactable, is not interested or is temporarily unavailable. 22 Decreased retention of minority donors may be attributable to cultural, social and economic reasons. Thus, an unknown proportion of potential donors will either be unavailable or unwilling for confirmatory testing or will be found not to be HLA matched on high-resolution typing. The likelihood that a potential donor will be available for confirmatory testing, and who on confirmatory testing is still considered an acceptable match, increases with the number of potential donors identified. It is therefore encouraging that 26.0% of SCD and 58.1% of thalassemia patients found three or more fully matched potential donors. The number of UCB units identified for SCD or thalassemia patients is relatively small in this study. In part this may be due to the low rate of acceptance of UCB donation among minorities. However, it also reflects the smaller number of UCB units as compared to bone marrow donors registered with the NMDP. This number has increased from 0 to 25 165 since the inception of the NMDP's UCB registry in 1999. Thus, a search of all available registries including the New York Blood Center and the University of Colorado UCB Blood Bank is likely to yield more UCB units for SCD and thalassemia patients. This was not pursued by the authors because of the technical and ethical difficulties of using information submitted to one registry for searching other registry databases. Thus, the availability of potential unrelated donors for thalassemia and SCD patients is likely to be better than that indicated in this study. We conclude that the majority of patients with SCD and thalassemia are likely to find at least one potential unrelated donor of hematopoietic stem cells. We recommend that a donor search be initiated whenever such a patient is considered to be a likely candidate for the consideration of URD HSCT.
